Johannes Steinfurt, MD,* Pietro Bernardo Dall’Aglio, MD,* Jannik Hugenschmidt, Judith Stuplich, MD, Markus Jäckel, MD, Eike Jordan, MD, Heiko Lehrmann, MD, Thomas S. Faber, MD, Alexander Gressler, MD, Amir S. Jadidi, MD, Dirk Westermann, MD, PHD, Thomas Arentz, MD, Luca Trolese, MD
doi : 10.1016/j.jacep.2022.05.010
Volume 8, Issue 9, September 2022, Pages 1067-1076
The Octaray (Biosense Webster) is a novel, multispline mapping catheter with 48 closely spaced microelectrodes enabling high-resolution electroanatomical mapping.
Luigi Di Biase, MD, PHD, a George Monir, MD, b Daniel Melby, MD, c Paul Tabereaux, MD,d Andrea Natale, MD,e Harish Manyam, MD,f Charles Athill, MD,g Craig Delaughter, MD,h Anshul Patel, MD,i Philip Gentlesk, MD,j Christopher Liu, MD, k Jeffrey Arkles, MD,l Hugh Thomas McElderry, J R, MD, m Jose Osorio, MD, n on behalf of the SURPOINT Postapproval Trial Investigators
doi : 10.1016/j.jacep.2022.06.007
Volume 8, Issue 9, September 2022, Pages 1077-1089
VISITAG SURPOINT (VS)–guided ablation of paroxysmal atrial fibrillation has demonstrated good short- and long-term success rates with low rates of complications in recent, predominantly European, studies. However, there is a lack of multicenter data from the United States.
Riccardo Cappato, MD, Hussam Ali, MD
doi : 10.1016/j.jacep.2022.07.018
Volume 8, Issue 9, September 2022, Pages 1090-1092
Jules Mesnier, MD,a Ignacio Cruz-González, MD, PH D, b Dabit Arzamendi, MD,c Xavier Freixa, MD, PHD, d Luis Nombela-Franco, MD, PHD, e Vicente Peral, MD, PH D, f Berenice Caneiro-Queija, MD,g Antonio Mangieri, MD,h Blanca Trejo-Velasco, MD,b Lluis Asmarats, MD,c Ander Regueiro, MD, P HD, d Angela McInerney, MD,e Caterina Mas-Lladó, MD, f Rodrigo Estevez-Loureiro, MD,g Alessandra Laricchia, MD, h Gilles O’Hara, MD, a Josep Rodés-Cabau, MD, PHD
doi : 10.1016/j.jacep.2022.06.012
Volume 8, Issue 9, September 2022, Pages 1093-1102
Left atrial appendage closure (LAAC) aims to prevent ischemic events in patients with atrial fibrillation. As a preventive procedure, early death after LAAC could render the procedure futile.
Salvatore J. Savona, MD, Emile G. Daoud, MD
doi : 10.1016/j.jacep.2022.07.009
Volume 8, Issue 9, September 2022, Pages 1103-1105
Martin van Zyl, MD, a Thomas P. Ladas, MD, PH D, a Jason A. Tri,a Omar Z. Yasin, MD, MS, a Adetola O. Ladejobi, MBBS, MPH,a Nicholas Y. Tan, MD, MS, a Georgios Christopoulos, MD, a Noah Schneider,a David J. Danitz, MS, b Darin Uecker, MS, b Christopher V. DeSimone, MD, P HD, a Ammar M. Killu, MBBS, a Elad Maor, MD, PH D, c Samuel J. Asirvatham, MD
doi : 10.1016/j.jacep.2022.06.002
Volume 8, Issue 9, September 2022, Pages 1106-1118
Pulsed electric field (PEF) ablation is an emerging modality for the treatment of cardiac arrhythmias. Data regarding effects on the interventricular septum are limited, and the optimal delivery protocol and electrode configuration remain undefined.
Jacob S. Koruth, MD, Iwanari Kawamura, MD
doi : 10.1016/j.jacep.2022.07.022
Volume 8, Issue 9, September 2022, Pages 1119-1121
Farshad Hosseini, MD, a Michael J. Thibert, MD,b,c Gaurav S. Gulsin, MBC HB, PHD, d Darra Murphy, MD,d George Alexander, P HD, b Jason G. Andrade, MD,b Nathaniel M. Hawkins, MBC HB, MD,b Zachary W. Laksman, MD,b John A. Yeung-Lai-Wah, MBC HB, b Santabhanu Chakrabarti, MD, b Matthew T. Bennett, MD, b Andrew D. Krahn, MD, b Marc W. Deyell, MD, MS C b
doi : 10.1016/j.jacep.2022.06.021
Volume 8, Issue 9, September 2022, Pages 1122-1132
The role of cardiac magnetic resonance (CMR) in the evaluation and management of patients with frequent premature ventricular complexes (PVCs) of unknown etiology remains unclear.
Edward P. Gerstenfeld, MD
doi : 10.1016/j.jacep.2022.07.004
Volume 8, Issue 9, September 2022, Pages 1133-1135
Richard J. Czosek, MD, a,b David S. Spar, MD,a,b Jeffrey B. Anderson, MD,a,b Philip R. Khoury, PH D, c Gregory Webster, MD, MPH
doi : 10.1016/j.jacep.2022.06.010
Volume 8, Issue 9, September 2022, Pages 1136-1144
Arrhythmias are common in single ventricle patients though their effect on outcomes during stage I palliation (S1P) is unclear.
Thomas Carberry, MD,a Jennifer Arzu, MPH,b Dana Coons, BA, a Nazia Husain, MD,a Nina Gotteiner, MD,a Gregory Webster, MD, MPH
doi : 10.1016/j.jacep.2022.06.003
Volume 8, Issue 9, September 2022, Pages 1145-1151
Fetal supraventricular tachycardia (SVT) is rare and proposed predictors of postnatal outcomes in fetal SVT have not been validated. Valid predictors can guide postnatal management.
Jordan E. Ezekian, MD, MPH, Elizabeth A. Stephenson, MD, MSC , CEPS-P ED
doi : 10.1016/j.jacep.2022.07.015
Volume 8, Issue 9, September 2022, Pages 1152-1154
Jeffrey Smietana, MD Gregory E. Supple, MD David S. Frankel, MD Robert D. Schaller, DO David Lin, MD Francis E. Marchlinski, MD *Pasquale Santangeli, MD, PhD
doi : 10.1016/j.jacep.2022.03.010
Volume 8, Issue 9, September 2022, Pages 1155-1157
Philipp Krisai, MD Mélèze Hocini, MD Nicolas Derval, MD Thomas Pambrun, MD Marion Constantin Robert Earl Josselin Duchateau, MD, PhD Frédéric Sacher, MD, PhD Michel Haïssaguerre, MD Pierre Jaïs, MD
doi : 10.1016/j.jacep.2022.04.004
Volume 8, Issue 9, September 2022, Pages 1157-1159
Annette Wacker-Gussmann, MD, PhDy *Janette F. Strasburger, MDy Ronald T. Wakai, PhD
doi : 10.1016/j.jacep.2022.04.012
Volume 8, Issue 9, September 2022, Pages 1159-1161
Elijah H. Bolin, MD Julie R. Whittington, MD Sarah T. Mehl, MD Diana Escalona-Vargas, PhD Hari Eswaran, PhD
doi : 10.1016/j.jacep.2022.05.011
Volume 8, Issue 9, September 2022, Pages 1161-1163
Piotr Futyma, MD, PhD Piotr Kułakowski, MD, PhD
doi : 10.1016/j.jacep.2022.05.020
Volume 8, Issue 9, September 2022, Page 1163
Elad Anter, MD Arwa Younis, MD Jacob S. Koruth, MD
doi : 10.1016/j.jacep.2022.08.009
Volume 8, Issue 9, September 2022, Page 1164
Seshadri Balaji, MBBS, PHD, a Dianne L. Atkins, MD, b Stuart Berger, MD,c Susan P. Etheridge, MD,d Maully J. Shah, MBBS, e on behalf of the Pediatric and Congenital Electrophysiology Society (PACES)
doi : 10.1016/j.jacep.2022.07.020
Volume 8, Issue 9, September 2022, Pages 1165-1172
Children, adolescents, and young adults with conditions such as cardiomyopathies and channelopathies are at higher risk of sudden cardiac death caused by lethal arrhythmias, especially ventricular fibrillation.
Satoshi Higuchi, MD, a Sunny S. Po, MD,b Stacey J. Howell, MD,a Melvin M. Scheinman, MD,a Henry H. Hsia, MD
doi : 10.1016/j.jacep.2022.05.013
Volume 8, Issue 9, September 2022, Pages 1173-1184
Sandeep Gautam, MD, MP H, a ,* Robert D. Schaller, DO, b, * Alexander Shinn, MD,a Joshua M. Cooper, MD,c Jeffery Winterfield, MD,d Joshua Payne, MD, d Leah John, MD,d Tolga Aksu, MD, e Oscar Vazquez-Diaz, MD,f Mustafa Omarov, MD, g Piotr Futyma, MD, PHD
doi : 10.1016/j.jacep.2022.05.012
Volume 8, Issue 9, September 2022, Pages 1185-1189
Do you want to add Medilib to your home screen?